510 related articles for article (PubMed ID: 20007560)
1. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease.
Hsieh MM; Kang EM; Fitzhugh CD; Link MB; Bolan CD; Kurlander R; Childs RW; Rodgers GP; Powell JD; Tisdale JF
N Engl J Med; 2009 Dec; 361(24):2309-17. PubMed ID: 20007560
[TBL] [Abstract][Full Text] [Related]
2. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype.
Hsieh MM; Fitzhugh CD; Weitzel RP; Link ME; Coles WA; Zhao X; Rodgers GP; Powell JD; Tisdale JF
JAMA; 2014 Jul; 312(1):48-56. PubMed ID: 25058217
[TBL] [Abstract][Full Text] [Related]
3. Nonmyeloablative Stem Cell Transplantation with Alemtuzumab/Low-Dose Irradiation to Cure and Improve the Quality of Life of Adults with Sickle Cell Disease.
Saraf SL; Oh AL; Patel PR; Jalundhwala Y; Sweiss K; Koshy M; Campbell-Lee S; Gowhari M; Hassan J; Peace D; Quigley JG; Khan I; Molokie RE; Hsu LL; Mahmud N; Levinson DJ; Pickard AS; Garcia JG; Gordeuk VR; Rondelli D
Biol Blood Marrow Transplant; 2016 Mar; 22(3):441-8. PubMed ID: 26348889
[TBL] [Abstract][Full Text] [Related]
4. Hematopoietic stem-cell transplantation for adults with sickle cell disease.
Abboud MR
N Engl J Med; 2009 Dec; 361(24):2380-1. PubMed ID: 20007564
[No Abstract] [Full Text] [Related]
5. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.
Kottaridis PD; Milligan DW; Chopra R; Chakraverty RK; Chakrabarti S; Robinson S; Peggs K; Verfuerth S; Pettengell R; Marsh JC; Schey S; Mahendra P; Morgan GJ; Hale G; Waldmann H; de Elvira MC; Williams CD; Devereux S; Linch DC; Goldstone AH; Mackinnon S
Blood; 2000 Oct; 96(7):2419-25. PubMed ID: 11001893
[TBL] [Abstract][Full Text] [Related]
6. Non-myeloablative human leukocyte antigen-matched related donor transplantation in sickle cell disease: outcomes from three independent centres.
Alzahrani M; Damlaj M; Jeffries N; Alahmari B; Singh A; Rondelli D; Tisdale JF; Saraf SL; Hsieh MM
Br J Haematol; 2021 Feb; 192(4):761-768. PubMed ID: 33534948
[TBL] [Abstract][Full Text] [Related]
7. Nonmyeloablative Matched Sibling Donor Hematopoietic Cell Transplantation in Children and Adolescents with Sickle Cell Disease.
Guilcher GMT; Monagel DA; Nettel-Aguirre A; Truong TH; Desai SJ; Bruce A; Shah RM; Leaker MT; Lewis VA
Biol Blood Marrow Transplant; 2019 Jun; 25(6):1179-1186. PubMed ID: 30772511
[TBL] [Abstract][Full Text] [Related]
8. Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation.
Grosskreutz C; Ross V; Scigliano E; Fruchtman S; Isola L
Biol Blood Marrow Transplant; 2003 Jul; 9(7):453-9. PubMed ID: 12869959
[TBL] [Abstract][Full Text] [Related]
9. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
10. Ex vivo immunological evaluation of stable mixed chimeric patients after matched related donor allogeneic transplantation in sickle cell disease.
Raines LN; Hsieh MM; Nassehi T; Drysdale CM; Tisdale JF; Uchida N
Cytotherapy; 2019 Dec; 21(12):1206-1215. PubMed ID: 31784240
[TBL] [Abstract][Full Text] [Related]
11. Impact of donor age on outcome after allogeneic hematopoietic cell transplantation.
Rezvani AR; Storer BE; Guthrie KA; Schoch HG; Maloney DG; Sandmaier BM; Storb R
Biol Blood Marrow Transplant; 2015 Jan; 21(1):105-12. PubMed ID: 25278458
[TBL] [Abstract][Full Text] [Related]
12. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia.
Iannone R; Casella JF; Fuchs EJ; Chen AR; Jones RJ; Woolfrey A; Amylon M; Sullivan KM; Storb RF; Walters MC
Biol Blood Marrow Transplant; 2003 Aug; 9(8):519-28. PubMed ID: 12931121
[TBL] [Abstract][Full Text] [Related]
13. In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation.
Kottaridis PD; Milligan DW; Chopra R; Chakraverty RK; Chakrabarti S; Robinson S; Peggs K; Verfuerth S; Pettengell R; Marsh JC; Schey S; Mahendra P; Morgan GJ; Hale G; Waldmann H; Ruiz de Elvira MC; Williams CD; Devereux S; Linch DC; Goldstone AH; MacKinnon S
Cytotherapy; 2001; 3(3):197-201. PubMed ID: 12171726
[TBL] [Abstract][Full Text] [Related]
14. Clinical evaluation of busulfan, cladribine and alemtuzumab as reduced intensity conditioning for stem cell transplantation.
Halaburda K; Marianska B; Warzocha K; Nasilowska-Adamska B; Szczepinski A; Tomaszewska A; Sawecka J; Skulimowska J
Ann Transplant; 2009; 14(2):7-12. PubMed ID: 19487787
[TBL] [Abstract][Full Text] [Related]
15. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen.
Chakraverty R; Peggs K; Chopra R; Milligan DW; Kottaridis PD; Verfuerth S; Geary J; Thuraisundaram D; Branson K; Chakrabarti S; Mahendra P; Craddock C; Parker A; Hunter A; Hale G; Waldmann H; Williams CD; Yong K; Linch DC; Goldstone AH; Mackinnon S
Blood; 2002 Feb; 99(3):1071-8. PubMed ID: 11807015
[TBL] [Abstract][Full Text] [Related]
16. Disease-specific hematopoietic cell transplantation: nonmyeloablative conditioning regimen for dyskeratosis congenita.
Dietz AC; Orchard PJ; Baker KS; Giller RH; Savage SA; Alter BP; Tolar J
Bone Marrow Transplant; 2011 Jan; 46(1):98-104. PubMed ID: 20383216
[TBL] [Abstract][Full Text] [Related]
17. Curative therapies: Allogeneic hematopoietic cell transplantation from matched related donors using myeloablative, reduced intensity, and nonmyeloablative conditioning in sickle cell disease.
Guilcher GMT; Truong TH; Saraf SL; Joseph JJ; Rondelli D; Hsieh MM
Semin Hematol; 2018 Apr; 55(2):87-93. PubMed ID: 29958564
[TBL] [Abstract][Full Text] [Related]
18. Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft.
Horwitz ME; Barrett AJ; Brown MR; Carter CS; Childs R; Gallin JI; Holland SM; Linton GF; Miller JA; Leitman SF; Read EJ; Malech HL
N Engl J Med; 2001 Mar; 344(12):881-8. PubMed ID: 11259721
[TBL] [Abstract][Full Text] [Related]
19. Partially mismatched pediatric transplants with allogeneic CD34(+) blood cells from a related donor.
Kawano Y; Takaue Y; Watanabe A; Takeda O; Arai K; Itoh E; Ohno Y; Teshima T; Harada M; Watanabe T; Okamoto Y; Abe T; Kajiume T; Matsushita T; Ikeda K; Endo M; Kuroda Y; Asano S; Tanosaki R; Yamaguchi K; Law P; McMannis JD
Blood; 1998 Nov; 92(9):3123-30. PubMed ID: 9787147
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcome of unrelated donor transplantation for AML using myeloablative conditioning incorporating pretransplant Alemtuzumab.
Das-Gupta EP; Russell NH; Shaw BE; Pearce RM; Byrne JL
Biol Blood Marrow Transplant; 2007 Jun; 13(6):724-33. PubMed ID: 17531783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
